Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)

NCT01481051 is registered in ClinicalTrials.gov with Mati Therapeutics Inc. as lead sponsor.

NCT NCT01481051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01481051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PPL GLAU 12: A Phase 2 Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)
Lead sponsor
Mati Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
September 30, 2012
Enrollment
57 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, ocular hypertension (oh)